Sarah Easaw
Medical Oncology · Lakewood, NJNPI 1265424253
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.8%), food and beverage and gifts — rather than concentrated in one kind of arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 21.6%. Reporting peaked in 2023 at $5,659 and has fallen 82.4% since, to $997 in 2024.
Across 407 payments — averaging $43.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$4K
- AstraZeneca$3K
- Novartis$2K
- Janssen Global Services, LLC$2K
- E.r. Squibb & Sons, L.L.C.$654
- Beigene USA, Inc.$576
- plus $5K from 40 others
What the payments were for
- Consulting fees$8,04946%
- Travel & lodging$8155%
- Food & beverage$5,85933%
- Education$7714%
- Gifts$1,0736%
- Other$9976%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$2,498
- BRUKINSA$1,050
- KISQALI$130
- Monoferric$125
- FOTIVDA$111
How this compares
$17,564 in reported general payments places this provider in the 75th percentile of 112 medical oncology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $9,856 |
| EliquisApixaban | 16 | $9,268 |
| Letrozole | 59 | $1,328 |
| Hydroxyurea | 31 | $1,093 |
| Anastrozole | 22 | $472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $315 | $9,85611 claims |
| PfizerEliquis | $463 | $9,26816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Lakewood
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.